These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32434404)

  • 21. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
    Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
    Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
    [No Abstract]   [Full Text] [Related]  

  • 22. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: A systematic review of real-world study data.
    Erdos J; Wild C
    Eur J Paediatr Neurol; 2022 Jul; 39():1-10. PubMed ID: 35533607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
    Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
    Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical perspectives: Treating spinal muscular atrophy.
    McPheron MA; Felker MV
    Mol Ther; 2024 Aug; 32(8):2489-2504. PubMed ID: 38894541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec -A Single Centre Experience.
    Friese J; Geitmann S; Holzwarth D; Müller N; Sassen R; Baur U; Adler K; Kirschner J
    J Neuromuscul Dis; 2021; 8(2):209-216. PubMed ID: 33427694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
    Malone DC; Dean R; Arjunji R; Jensen I; Cyr P; Miller B; Maru B; Sproule DM; Feltner DE; Dabbous O
    J Mark Access Health Policy; 2019; 7(1):1601484. PubMed ID: 31105909
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy.
    Jalali A; Rothwell E; Botkin JR; Anderson RA; Butterfield RJ; Nelson RE
    J Pediatr; 2020 Dec; 227():274-280.e2. PubMed ID: 32659229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Abeparvovec.
    Matesanz SE; Curry C; Gross B; Rubin AI; Linn R; Yum SW; Kichula EA
    J Child Neurol; 2020 Oct; 35(11):717-723. PubMed ID: 32515646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy.
    Lee M; França UL; Graham RJ; McManus ML
    Pediatr Neurol; 2019 Mar; 92():3-5. PubMed ID: 30591237
    [No Abstract]   [Full Text] [Related]  

  • 31. Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs.
    Ballreich J; Ezebilo I; Khalifa BA; Choe J; Anderson G
    J Manag Care Spec Pharm; 2022 Jan; 28(1):39-47. PubMed ID: 34949120
    [No Abstract]   [Full Text] [Related]  

  • 32. [Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 : Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)].
    Ziegler A; Wilichowski E; Schara U; Hahn A; Müller-Felber W; Johannsen J; von der Hagen M; von Moers A; Stoltenburg C; Saffari A; Walter MC; Husain RA; Pechmann A; Köhler C; Horber V; Schwartz O; Kirschner J
    Nervenarzt; 2020 Jun; 91(6):518-529. PubMed ID: 32394004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Onasemnogene Abeparvovec: First Global Approval.
    Hoy SM
    Drugs; 2019 Jul; 79(11):1255-1262. PubMed ID: 31270752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The health economics of cell and gene therapies.
    Beswick L
    Handb Clin Neurol; 2024; 205():155-167. PubMed ID: 39341653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
    Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
    Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series.
    Chand DH; Zaidman C; Arya K; Millner R; Farrar MA; Mackie FE; Goedeker NL; Dharnidharka VR; Dandamudi R; Reyna SP
    J Pediatr; 2021 Apr; 231():265-268. PubMed ID: 33259859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the Value of Nusinersen for Spinal Muscular Atrophy: A Comparative Analysis of Reimbursement Submission and Appraisal in European Countries.
    Blonda A; Barcina Lacosta T; Toumi M; Simoens S
    Front Pharmacol; 2021; 12():750742. PubMed ID: 35126102
    [No Abstract]   [Full Text] [Related]  

  • 38. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    Chand D; Mohr F; McMillan H; Tukov FF; Montgomery K; Kleyn A; Sun R; Tauscher-Wisniewski S; Kaufmann P; Kullak-Ublick G
    J Hepatol; 2021 Mar; 74(3):560-566. PubMed ID: 33186633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Note: Zolgensma data manipulation.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):129. PubMed ID: 31581156
    [No Abstract]   [Full Text] [Related]  

  • 40. Spinal Muscular Atrophy in the Treatment Era.
    Waldrop MA; Elsheikh BH
    Neurol Clin; 2020 Aug; 38(3):505-518. PubMed ID: 32703464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.